Loading...
Market
What will be the primary challenge reported in the first year post-implantation of the BiVACOR titanium heart by the end of 2024?
2
Resolution / Starting Odds
Mechanical failure • 25%
Patient immune response • 25%
Surgical complications • 25%
Other • 25%
Medical reports, news articles, BiVACOR press releases
Story
Doctors Successfully Implant BiVACOR Titanium Heart Using Maglev Technology in 58-Year-Old Man
Aug 3, 2024, 10:56 AM
In a groundbreaking medical achievement, doctors in the United States have successfully implanted a fully mechanical titanium heart in a 58-year-old man. The heart, developed by BiVACOR, utilizes Maglev technology, which is also used in high-speed rail travel, to function effectively. This world-first implantation has kept the patient alive for days, marking a significant milestone in medical science. Experts believe the impact of this innovation will be tremendous, potentially revolutionizing the future of heart transplants and artificial organs.
View original story
Similar markets
Infection • 25%
Device malfunction • 25%
Rejection • 25%
No major complications • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
Cleveland Clinic • 25%
Mayo Clinic • 25%
Johns Hopkins Hospital • 25%
Other • 25%
Yes • 50%
No • 50%
Government grants • 25%
Private investors • 25%
Pharmaceutical companies • 25%
Non-profit organizations • 25%
Immune rejection • 25%
Infection risk • 25%
Ethical concerns • 25%
Supply chain issues • 25%
Successful with no complications • 25%
Successful with minor complications • 25%
Successful with major complications • 25%
Unsuccessful • 25%
Technical issues • 25%
Regulatory hurdles • 25%
Funding shortages • 25%
Market competition • 25%
Regulatory issues • 25%
Technical failures • 25%
Patient recruitment difficulties • 25%
No major challenges • 25%
Rejection issues • 25%
Infection complications • 25%
Ethical concerns • 25%
Other challenges • 25%